Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sphingosine-1-phosphate cross-talks to Notch via a S1PR1-Dll4-MPDZ complex to regulate endothelial barrier function.

bioRxiv : the preprint server for biology·2026
Same author

TusDCB-mediated tRNA sulfur modification is required for virulence and intestinal fitness in enterohemorrhagic <i>Escherichia coli</i>.

Infection and immunity·2026
Same author

Metformin suppresses β-cell apoptosis under ER stress by inhibiting protein translation.

Metabolism: clinical and experimental·2026
Same author

Apolipoprotein M: Structural insights, functional roles, and therapeutic approaches in vascular disease.

The Journal of biological chemistry·2026
Same author

S1PR1 signaling biases neutrophils toward long-lived low-inflammatory functional states.

bioRxiv : the preprint server for biology·2026
Same author

Expression-driven genetic dependency reveals targets for precision oncology.

GigaScience·2026

Related Experiment Video

Updated: May 18, 2026

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
12:27

A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

Published on: June 8, 2022

Fine-tuning S1P therapeutics.

Hideru Obinata, Timothy Hla

    Chemistry & Biology
    |September 25, 2012
    PubMed
    Summary
    This summary is machine-generated.

    Researchers developed NIBR-0213, a Sphingosine 1-phosphate receptor-1 (S1P(1)) antagonist. This compound targets autoimmune inflammation in multiple sclerosis, potentially offering a better safety profile by avoiding heart rate side effects.

    More Related Videos

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    Related Experiment Videos

    Last Updated: May 18, 2026

    A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors
    12:27

    A Pipeline to Investigate the Structures and Signaling Pathways of Sphingosine 1-Phosphate Receptors

    Published on: June 8, 2022

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
    07:04

    Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

    Published on: May 2, 2025

    Area of Science:

    • Immunology
    • Pharmacology
    • Neuroscience

    Background:

    • Sphingosine 1-phosphate receptor-1 (S1P(1)) is a key regulator of lymphocyte trafficking and is implicated in autoimmune diseases like multiple sclerosis.
    • Current S1P receptor modulators face challenges due to adverse effects, including bradycardia.
    • Developing selective S1P(1) modulators is crucial for improving therapeutic outcomes in multiple sclerosis.

    Discussion:

    • NIBR-0213 acts as a competitive antagonist for S1P(1), demonstrating the potential for targeted modulation of this receptor.
    • The compound effectively inhibits autoimmune inflammation, a hallmark of multiple sclerosis pathogenesis.
    • Crucially, NIBR-0213 appears to spare the bradycardic effects often associated with S1P receptor modulation.

    Key Insights:

    • NIBR-0213 represents a promising therapeutic candidate for multiple sclerosis by selectively targeting S1P(1).
    • This selective antagonism offers a potential strategy to mitigate the cardiovascular side effects linked to broader S1P receptor modulation.
    • The findings highlight the importance of fine-tuning S1P(1) modulators for an improved efficacy-to-adverse event ratio.

    Outlook:

    • Further research into NIBR-0213 and similar selective S1P(1) modulators could lead to next-generation treatments for multiple sclerosis.
    • Optimizing S1P(1) modulators may yield novel immune modulators with enhanced safety and efficacy profiles.
    • This work paves the way for developing safer and more effective therapies for immune-mediated inflammatory diseases.